Platelet-raising injections generally refer to human thrombopoietin, which is administered for the same duration as the platelet-increasing drug (eltrombopag) and is usually given for 14 days. The use of platelet-raising injections requires clarification of the etiology of the disease, including aplastic anemia, acute leukemia, and primary immune thrombocytopenia, which should be treated in conjunction with the primary disease, such as acute myelogenous leukemia treated with cytarabine chemotherapy, and selection of appropriate platelet-raising medications. Platelet-raising injections are generally recommended to be given for 14 days. The efficacy of platelet-raising injections varies among patients; some patients may be able to normalize their platelet counts after 7 injections; some patients may not be able to do so even after 14 injections. During the period of platelet-raising injections, changes in platelet counts in the blood counts should be noted. Adverse reactions include rash, fever, diarrhea, etc. It is contraindicated in patients who are allergic to the product. The above medications should be used under the supervision of a physician.